Search hospitals > Pennsylvania > York
Cancer Care Associates of York
Claim this profileYork, Pennsylvania 17403
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Prostate Cancer
73 reported clinical trials
4 medical researchers
Summary
Cancer Care Associates of York is a medical facility located in York, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Prostate Cancer and other specialties. Cancer Care Associates of York is involved with conducting 73 clinical trials across 107 conditions. There are 4 research doctors associated with this hospital, such as Chanh T. Huynh, Dan Sotirescu, Joseph Kannarkatt, and Ikechukwu I. Akunyili.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Chanh T. HuynhAdams Cancer Center1 year of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
37 drugs studied
Dan SotirescuEphrata Cancer Center4 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
28 drugs studied
Joseph KannarkattWellSpan Medical Oncology and Hematology3 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
31 drugs studied
Ikechukwu I. AkunyiliEphrata Cancer Center1 year of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
3 reported clinical trials
8 drugs studied
Clinical Trials running at Cancer Care Associates of York
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma
Recurrence
Lung Carcinoma
ALK Gene Rearrangement
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Care Associates of York?
Cancer Care Associates of York is a medical facility located in York, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Prostate Cancer and other specialties. Cancer Care Associates of York is involved with conducting 73 clinical trials across 107 conditions. There are 4 research doctors associated with this hospital, such as Chanh T. Huynh, Dan Sotirescu, Joseph Kannarkatt, and Ikechukwu I. Akunyili.